{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:16:18Z","timestamp":1740147378887,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s11845-018-1764-7","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T13:04:54Z","timestamp":1518786294000},"page":"1115-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emphasis of FAS\/FASL gene polymorphism in patients with non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7825-8808","authenticated-orcid":false,"given":"Cavit","family":"Ceylan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Yah\u015fi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elife","family":"\u00d6zt\u00dcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulay","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"issue":"3","key":"1764_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"3","key":"1764_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comperat E et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462\u2013475. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.06.020","journal-title":"Eur Urol"},{"issue":"6 Suppl 4","key":"1764_CR3","first-page":"S199","volume":"3","author":"A Zlotta","year":"2009","unstructured":"Zlotta A, Fleshner N, Jewett M (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3(6 Suppl 4):S199\u2013S205","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"1764_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"T Zuiverloon","year":"2012","unstructured":"Zuiverloon T, Nieuweboer A, Vekony H, Kirkels W, Bangma C, Zwarthoff E (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61(1):128\u2013145. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2011.09.026","journal-title":"Eur Urol"},{"key":"1764_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbacli.2015.06.002","volume":"4","author":"A Kiselyov","year":"2015","unstructured":"Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V (2015) Treatment of non-muscle invasive bladder cancer with bacillus Calmette-Guerin (BCG): biological markers and simulation studies. Bba Clin 4:27\u201334. \n                    https:\/\/doi.org\/10.1016\/j.bbacli.2015.06.002","journal-title":"Bba Clin"},{"issue":"44","key":"1764_CR6","first-page":"E41","volume":"32","author":"L Lima","year":"2014","unstructured":"Lima L, Ferreira J, Tavares A et al (2014) FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer. Urol Oncol 32(44):E41\u2013E47","journal-title":"Urol Oncol"},{"issue":"5","key":"1764_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bju.12844","volume":"116","author":"L Lima","year":"2015","unstructured":"Lima L, Oliveira D, Ferreira J et al (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a southern Europe population. BJU Int 116(5):753\u2013763. \n                    https:\/\/doi.org\/10.1111\/bju.12844","journal-title":"BJU Int"},{"key":"1764_CR8","doi-asserted-by":"publisher","first-page":"176741","DOI":"10.1155\/2013\/176741","volume":"2013","author":"B Moudi","year":"2013","unstructured":"Moudi B, Salimi S, Farajian Mashhadi F, Sandoughi M, Zakeri Z (2013) Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. ScientificWorldJournal 2013:176741","journal-title":"ScientificWorldJournal"},{"issue":"9","key":"1764_CR9","first-page":"3729","volume":"6","author":"S Brandau","year":"2000","unstructured":"Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, B\u00f6hle A (2000) Perforin-mediated lysis of tumor cells by mycobacterium bovis bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6(9):3729\u20133738","journal-title":"Clin Cancer Res"},{"key":"1764_CR10","first-page":"9859021","volume":"2016","author":"N Zhang","year":"2016","unstructured":"Zhang N, Jiang G, Liu X, Na R, Wang X, Xu J (2016) Prediction of bacillus Calmette-Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies. Biomed Res Int 2016:9859021","journal-title":"Biomed Res Int"},{"issue":"4","key":"1764_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.urolonc.2013.10.013","volume":"32","author":"H Kang","year":"2014","unstructured":"Kang H, Tchey D, Yan C et al (2014) The predictive value of Gstt1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Urol Oncol 32(4):458\u2013465. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2013.10.013","journal-title":"Urol Oncol"},{"issue":"4","key":"1764_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13547500902818246","volume":"14","author":"D Ahirwar","year":"2009","unstructured":"Ahirwar D, Agrahari A, Mandhani A, Mittal R (2009) Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4):213\u2013218. \n                    https:\/\/doi.org\/10.1080\/13547500902818246","journal-title":"Biomarkers"},{"issue":"1-2","key":"1764_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2006.06.009","volume":"35","author":"B Basturk","year":"2006","unstructured":"Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B (2006) Cytokine gene polymorphisms can alter the effect of bacillus Calmette-Guerin (Bcg) immunotherapy. Cytokine 35(1-2):1\u20135. \n                    https:\/\/doi.org\/10.1016\/j.cyto.2006.06.009","journal-title":"Cytokine"},{"issue":"5","key":"1764_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00432-009-0717-y","volume":"136","author":"R Gangwar","year":"2010","unstructured":"Gangwar R, Mandhani A, Mittal R (2010) Xpc gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. J Cancer Res Clin Oncol 136(5):779\u2013786. \n                    https:\/\/doi.org\/10.1007\/s00432-009-0717-y","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1764_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4161\/cbt.7.5.5763","volume":"7","author":"R Mittal","year":"2008","unstructured":"Mittal R, Singh R, Manchanda P et al (2008) Xrcc1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther 7(5):645\u2013650. \n                    https:\/\/doi.org\/10.4161\/cbt.7.5.5763","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"1764_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.coph.2004.03.008","volume":"4","author":"A Houston","year":"2004","unstructured":"Houston A, O'connell J (2004) The FAS signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4(4):321\u2013326. \n                    https:\/\/doi.org\/10.1016\/j.coph.2004.03.008","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"1764_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1044-579X(02)00017-2","volume":"12","author":"E Reichmann","year":"2002","unstructured":"Reichmann E (2002) The biological role of the FAS\/FASL system during tumor formation and progression. Semin Cancer Biol 12(4):309\u2013315. \n                    https:\/\/doi.org\/10.1016\/S1044-579X(02)00017-2","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1764_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/carcin\/bgp016","volume":"30","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30(3):487\u2013493. \n                    https:\/\/doi.org\/10.1093\/carcin\/bgp016","journal-title":"Carcinogenesis"},{"issue":"4","key":"1764_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0002-9440(10)63910-7","volume":"162","author":"D Chopin","year":"2003","unstructured":"Chopin D, Barei-Moniri R, Maille P et al (2003) Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 162(4):1139\u20131149. \n                    https:\/\/doi.org\/10.1016\/S0002-9440(10)63910-7","journal-title":"Am J Pathol"},{"issue":"4","key":"1764_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.fpc.0000194425.58511.a7","volume":"16","author":"C Li","year":"2006","unstructured":"Li C, Wu W, Liu J, Qian L, Li A, Yang K, Wei Q, Zhou J, Zhang Z (2006 Apr) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in South China: a case-control analysis. Pharmacogenet Genomics 16(4):245\u2013251. \n                    https:\/\/doi.org\/10.1097\/01.fpc.0000194425.58511.a7","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"1764_CR21","first-page":"397","volume":"28","author":"L Verim","year":"2014","unstructured":"Verim L, Timirci-Kahraman O, Akbulut H, Akbas A, Ozturk T, Turan S, Yaylim I, Ergen A, Ozturk O, Isbir T (2014 May-Jun) Functional genetic variants in apoptosis associated Fas and Fasl genes and risk of bladder cancer in a Turkish population. In Vivo 28(3):397\u2013402","journal-title":"In Vivo"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-018-1764-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-018-1764-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-018-1764-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T21:42:09Z","timestamp":1550353329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-018-1764-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1007\/s11845-018-1764-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"14 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}